← Back to Search

Repetitive Transcranial Magnetic Stimulation

Dash Protocol for Depression (Comfort Start Trial)

N/A

Waitlist Available

Research Sponsored by Neuronetics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 days

Awards & highlights

Comfort Start Trial Summary

This trial will compare the standard NeuroStar TMS protocol with a new feature that alters the strength of the pulses, in order to find which is more comfortable for patients.

Eligible Conditions

Depression

Comfort Start Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Evaluate comfort of TMS treatment

Secondary outcome measures

Ability to reach prescribed treatment intensity

Comfort Start Trial Design

2Treatment groups

Active Control

Group I: Dash ProtocolActive Control1 Intervention

Patients will be randomized after consent to receive standard Dash protocol

Group II: Modified Dash protocol with the New feature enabledActive Control1 Intervention

Patients will be randomized after consent to receive modified Dash protocol with the New feature enabled

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NeuroneticsLead Sponsor

22 Previous Clinical Trials

7,512 Total Patients Enrolled

12 Trials studying Depression

7,087 Patients Enrolled for Depression

Steve A Erickson, BSStudy DirectorNeuronetics

Media Library

NeuroStar New Treatment Feature (Repetitive Transcranial Magnetic Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05535062 — N/A

Depression Research Study Groups: Dash Protocol, Modified Dash protocol with the New feature enabled

Depression Clinical Trial 2023: NeuroStar New Treatment Feature Highlights & Side Effects. Trial Name: NCT05535062 — N/A

NeuroStar New Treatment Feature (Repetitive Transcranial Magnetic Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05535062 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially be a part of this medical experiment?

"This clinical study seeks 40 patients diagnosed with major depressive disorder (MDD) between the ages of 22 and 70. Notably, applicants must fulfill the following requirements: 1. Be aged from 22-70., 2. Qualify for transcranial magnetic stimulation (TMS) therapy as per FDA-cleared treatment guidelines evaluated by their treating physician., 3. Have a MDD diagnosis according to applicable DSM criteria, ICD-9 or ICD-10 codes., 4. Not take any analgesic pain medication prior to TMS sessions., 5. Consent to receive TMS outside of this research project via written agreement., 6 Agree"

Answered by AI

Is admittance to this clinical experiment restricted solely to individuals aged 65 or older?

"As stipulated by the criteria for this medical trial, prospective participants must be between 22 and 70. For patients younger than 18 years old, there are 192 trials available; conversely, those over 65 can explore 967 studies."

Answered by AI

Are there still opportunities for participation in this research endeavor?

"According to clinicaltrials.gov, this particular trial is not currently enrolling subjects. Initially posted on November 1st 2022, it was last updated a month later and has yet to reopen recruitment. Fortunately, there are 1294 other studies presently recruiting participants at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

2022. "Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05535062.